Patient versus clinician preferences for chemotherapy in non-small-cell lung cancer

Author： Long Anne   Ferraro Danielle   Stockler Martin   Blinman Prunella  

Publisher： Future Medicine

ISSN： 1758-1966

Source： Lung Cancer Management, Vol.2, Iss.6, 2013-12, pp. : 527-536

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Multiple myeloma emerging after chemotherapy for non-small-cell lung cancer

By Marinopoulos Spyridon   Skorda Lamprini   Karatapanis Stylianos   Rasidakis Antonis  

Medical Oncology, Vol. 25, Iss. 4, 2008-12 ,pp. : 415-418

Humana Press, Inc

Access to resources Recommend Favorite

Chemotherapy: still an essential player in non-small-cell lung cancer treatment?

By Ferreira Carlos Gil   Montella Tatiane Caldas   Baldotto Clarissa Seródio   Domingues Pedro Masson  

Lung Cancer Management, Vol. 2, Iss. 5, 2013-10 ,pp. : 381-390

Future Medicine

Access to resources Recommend Favorite

Optimizing Chemotherapy in Non-Small Cell Lung Cancer

By Rosell Rafael  

American Journal of Cancer, Vol. 5, Iss. 4, 2006-01 ,pp. : 211-212

Adis International

Access to resources Recommend Favorite

Adjuvant Chemotherapy for Non-Small Cell Lung Cancer

By Solomon Benjamin   Bunn Paul A.  

Cancer Investigation, Vol. 25, Iss. 4, 2007-06 ,pp. : 217-225

Informa Healthcare

Access to resources Recommend Favorite

Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line

By Mortenson Melinda   Schlieman Michael   Virudachalam Subbulakshmi   Bold Richard  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 4, 2004-10 ,pp. : 343-353

Springer Publishing Company

Access to resources Recommend Favorite